

# Report from the World Economic Forum 2020 Antimicrobial Resistance (AMR) Benchmark

PACCARB Public Meeting

Fatema Rafiqi, Ph.D., *Research Programme Manager*

*26 February 2020*

# 2020 AMR Benchmark launched on 21 January

## Bloomberg



Business

### In Superbug War, Reliance on Just a Few Drugmakers Fuels Concern

By James Paton  
21 January 2020 14:00 CET

## BL BusinessLine

### Access to antibiotics as much a concern as antimicrobial resistance, says report



More people die from lack of access to a drug, than resistance, says Jayasree Iyer, Executive Director of Access to Medicine Foundation

## REUTERS

MEDIA - PUBLISHED ON 21 JAN 2020

### Pharma firms not making enough progress against superbugs: report

## The Telegraph

News Global ... Science & Disease

### World 'precariously reliant' on handful of companies developing drugs to treat superbugs, report warns

share | Save



The world is "precariously reliant" on just a handful of companies to develop new antibiotics, running the risk of a rise in superbugs, a report has warned.

## The Guardian



### Antibiotics

### Lack of antibiotics in low income countries 'worsening superbugs threat'

Only three new treatments available in 10 or more poorer countries, report finds

## NOS




### Aanpak wereldwijde verspreiding antibioticaresistentie lukt onvoldoende

## STAT

PHARMALOT STAT+

### Pharma is making some effort to fight superbugs, but progress is 'patchy'

By ED SILVERMAN @Pharmalot  
JANUARY 21, 2020



## DW Made for minds.

RESISTENZEN

### Medikamente: Forschung nach Antibiotika kommt schleppend voran

Antibiotika-resistente Bakterien bedrohen unsere Gesundheit. Nur noch wenige forschende Pharmaunternehmen versuchen, neue Medikamente auf den Markt zu bringen. Und sie versuchen, Verschreibungen einzuschränken.





# Official launch at WEF Annual Meeting in Davos



# The Access to Medicine Foundation

The Foundation guides and incentivises pharmaceutical companies to improve access to medicine by:

- conducting research on what companies do
- comparing their performance one against the other
- identifying best practices and areas for improvements

The Foundation has a team of 10+ analysts who cover pharmaceutical companies on a daily basis.



Ministry of Foreign Affairs

BILL & MELINDA  
GATES *foundation*




Ministry of Health, Welfare and Sport

# 2020 AMR Benchmark

## What we measure

# Company scope for the 2020 AMR Benchmark



+ Companies newly added in 2020 AMR Benchmark  
\* Companies that declared bankruptcy between 2018-2019



# Analytical framework: Three research areas

## A RESEARCH & DEVELOPMENT



- A.1 R&D investments
- A.2.1 Pipeline size
- A.2.2 Novelty of pipeline
- A.2.3 Vaccines in the pipeline
- A.2.4 Projects targeting critical priorities
- A.3 Intellectual capital sharing
- A.4 Access & stewardship planning

## B RESPONSIBLE MANUFACTURING



- B.1 Environmental risk-management strategy
- B.2 Disclosure on environmental risk management
- B.3 Manufacturing high-quality antibacterials

## C APPROPRIATE ACCESS & STEWARDSHIP




- C.1.1 Registration of on-patent products
- C.1.2 Registration of off-patent/gen. products
- C.2.1 Accessibility of on-patent products
- C.2.2 Accessibility of off-patent/gen. products
- C.3 Ensuring continuous supply
- C.4 Educational stewardship activities
- C.5 Appropriate promotional practices
- C.6 Stewardship-oriented packaging adapt.
- C.7 Antimicrobial surveillance

# 2020 AMR Benchmark Report highlights





# 2020 AMR Benchmark at a glance



4 KEY FINDINGS

3 RESEARCH AREAS

12 BEST PRACTICES



21 R&D PIPELINES FOR PRIORITY BACTERIA & FUNGI


30 DETAILED COMPANY REPORT CARDS

# More companies join the leaders, yet progress is slow


## ANTIMICROBIAL RESISTANCE BENCHMARK – 2020

● Performance in 2020 ● Room to improve


Large R&D-based companies



Generic medicine manufacturers



Pharmaceutical SMEs



## Key Findings

- **Signs of movement in access and stewardship planning in R&D, from a low base**
  - Pharma companies have plans for access and stewardship for 8 out of 32 key candidate antibiotics (25%), up from 2 of 28 (7%) in 2018
- **Progress in how pharma companies tackle overselling antimicrobials**
  - 10 companies are either decoupling bonuses from sales volumes or refraining from deploying sales agents for antimicrobials
- **Publicly sharing AMR surveillance results is common practice, yet only one company shares raw data**
  - Pfizer is the first company to share raw data on the spread of resistance in an open-access online register

# Calls for action intensify at WEF launch for 2020 AMR Benchmark

- High-Level Panel Session discussing the Benchmark results, the case for reforming the antibiotics market, and the announcement of a new initiative to mobilise investors on AMR
- **Key Highlights:**
  - Procurers are interested in using our data on company performance to integrate AMR consideration in their buying process and inform procurement decisions
    - Global Fund to Fight AIDS, Tuberculosis and Malaria is the biggest purchaser of antimicrobials in the world
  - Investors are interested in our data to integrate AMR in their investment decisions and engagement with companies.
    - Launch of the *Investor Year of Action on Antimicrobial Resistance*
      - *Collaboration between the UK Government, Access to Medicine Foundation, the FAIRR Initiative and the Principals for Responsible Investment*



# 2020 AMR Benchmark

Fatema Rafiqi, Research Programme Manager,  
[fraciqi@accesstomedicinefoundation.org](mailto:fraciqi@accesstomedicinefoundation.org)